the combination index was less than 0.2 for all effective doses, with 19.8-fold and 5-fold shifts in the IC 50 (0.5 M for HG-3 and 0.38 M for MEC-1 cell line) ( Supplemental Table 3 , Supplemental Figure 8 )
Price 50.00 INR/ Piece Minimum Order Quantity 5000 Pieces Supply Ability 10000000 Pieces Per Day Delivery Time 35 Days Main Domestic Market , All India, South India, Central India, West India, North India, East India, Gujarat, Karnataka, Kerala, Lakshadweep, Mizoram, Meghalaya, Manipur, Andhra Pradesh, Bihar, Chandigarh, Daman and Diu, Goa, Jharkhand, Odisha, Punjab, Assam, Delhi, Dadra and Nagar Haveli, Andaman and Nicobar Islands, Arunachal Pradesh, Chhattisgarh, Haryana, Himachal Pradesh, Jammu and Kashmir, Madhya Pradesh, Maharashtra, Nagaland, Rajasthan, Sikkim, Tamil Nadu, Telangana, Tripura, Pondicherry, Uttar Pradesh, Uttarakhand, West Bengal Main Export Market(s) Asia, Middle East, Africa Price: 50 100 200 250 500 1000+ More Products in Injection Manufacturing (Lyophilized And Liquid) Category Iron Sucrose Injection Price 249 INR / Piece Minimum Order Quantity : 100 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid Carboplatin Injection Price 100.00 INR / Piece Minimum Order Quantity : 50 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid Teicoplanin Injection Price 50 INR / Piece Minimum Order Quantity : 5000 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid Tobramycin Sulphate Injection Price 10.00 INR / Piece Minimum Order Quantity : 5000 Pieces Drug Type : Injection Origin of Medicine : India Dosage : As per suggestion Physical Form : Liquid
We sought to investigate the efficacy and safety of an oral glutathione supplement comprising L-glutathione (fermentation), ascorbic acid, alpha-lipoic acid, and zinc (as zinc aspartate) as a skin-lightening agent
However, larger trials have not consistently shown mortality benefit (Rank et al., Crit Care Med, 2000) [41]
Over the 52-week-long trial, hypomagnesemia (7.2%) was the most common treatment-related adverse event and mild to moderate constipation (6.3%) was the most common GI adverse event
